Market revenue in 2021 | USD 51.3 million |
Market revenue in 2030 | USD 325.2 million |
Growth rate | 22.8% (CAGR from 2021 to 2030) |
Largest segment | Serum biomarkers |
Fastest growing segment | Hepatic Fibrosis Biomarkers |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers |
Key market players worldwide | Genfit SA, Siemens AG, Quest Diagnostics Inc, AstraZeneca PLC, Meridian Bioscience, Labcorp Holdings Inc, Pfizer Inc, Bristol-Myers Squibb Co |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non-alcoholic steatohepatitis biomarkers market will help companies and investors design strategic landscapes.
Serum biomarkers was the largest segment with a revenue share of 32.75% in 2021. Horizon Databook has segmented the Germany non-alcoholic steatohepatitis biomarkers market based on serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers covering the revenue growth of each sub-segment from 2018 to 2030.
Germany has a large number of institutes and universities that are actively promoting the adoption of biomarkers in drug development for research purposes, thereby boosting revenue generation in this country. Government institutes are collaborating with other research institutes to improve the healthcare facility in the country.
Currently, the University Hospital Knapp schafts krankenhaus, along with Max Planck Institute for Dynamics of Complex Technical Systems, Bielefeld University, and others, is engaged in the discovery and development of biomarkers for NASH patients with or without hepatocellular carcinoma using fecal meta proteomics.
In addition, research institutes targeted the identification of diagnostic biomarkers, medical data and the fecal metaproteome of 32 NASH patients & 29 HCC patients in comparison with 19 healthy controls were analyzed.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany non-alcoholic steatohepatitis biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into Germany non-alcoholic steatohepatitis biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account